Attributions for psychobiological changes in ecstasy/MDMA and other polydrug users

Journal of Psychopharmacology

Volumn 23, Issue 7, 2009, Pages 745-758

  Soar, K ^a   Parrott, A ^b   Turner, J ^a  

^a UNIVERSITY OF EAST LONDON   (United Kingdom)

^b SWANSEA UNIVERSITY   (United Kingdom)

Author keywords

Attributions; Ecstasy MDMA; Polydrug use; Problems; Psychopathology

Indexed keywords

3,4 METHYLENEDIOXYMETHAMPHETAMINE; ALCOHOL; ECSTASY; NICOTINE; UNCLASSIFIED DRUG;

ADULT; ALCOHOLISM; ARTICLE; ATTRIBUTABLE RISK; CLINICAL ASSESSMENT; CONTROLLED STUDY; DISEASE ASSOCIATION; DRUG DEPENDENCE; DRUG EFFECT; DRUG USE; FEMALE; HUMAN; LIFE EVENT; LIFESTYLE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTIPLE DRUG ABUSE; PERSONAL EXPERIENCE; PRIORITY JOURNAL; PSYCHOBIOLOGY; SMOKING; SOCIAL PROBLEM; TOBACCO DEPENDENCE;

ADULT; ATTITUDE; DRUG USERS; FEMALE; HUMANS; LIFE CHANGE EVENTS; MALE; MENTAL DISORDERS; N-METHYL-3,4-METHYLENEDIOXYAMPHETAMINE; QUESTIONNAIRES; STREET DRUGS; SUBSTANCE-RELATED DISORDERS;

EID: 69049099167     PISSN: 02698811     EISSN: 14617285     Source Type: Journal    
DOI: 10.1177/0269881108092594     Document Type: Article

References (51)

1. Alati R. Kinner SA. Hayatbakhsh MR. Mamun AA. Najman JM. Williams GM. (2008) Pathways to ecstasy use in young adults: Anxiety, depression or behavioural deviance. Drug Alcohol Depend 92: 108-115.
2. Arria AM. Yacoubian GS. Fost E. (2002) Ecstasy use among club rave attendees. Arch Paediatric Adolescent Medicine 156: 295-296.
3. Cami J. Farre M. Mas M. Roset PN. Pausevida S. Mas A. (2000) Human pharmacology of 3,4-methylenedioxymethamphetamine ("ecstasy"). psychomotor performance and subjective effects. J Clin Psychopharmacol 20: 455-466.
4. Cohen J. (1988) Statistical power analysis for the behavioural sciences. Second ed. Hillsdale: Erlbaum.
5. Cohen RS. (1995) Subjective reports on the effects of the MDMA ("Ecstasy") experience in humans. Prog. Neuro-Psychopharmacol and Biol. Psychiat 19: 1137-1145.
6. Curran HV. (2000) Is MDMA ('Ecstasy') neurotoxic in humans? An overview of evidence and of methodological problems in research. Neuropsychobiology 42: 34-41.
7. Curran VH. Rees H. Hoare T. Hoshi R. Bond A. (2004) Empathy and aggression: two faces of ecstasy? A study of interpretative cognitive bias and mood change in ecstasy users. Psychopharmacology (Berl) 173: 425-433.
8. Daumann J. Hensen G. Thimm B. Rexk M. Till B. Gouzoulis-Mayfrank E. (2004) Self-reported psychopathological symptoms in abstinent recreational ecstasy (MDMA) users are mainly associated with regular cannabis use: further evidence from a combined cross-sectional/longitudinal investigation. Psychopharmacology 180: 607-611.
9. Daumann J. Pelz S. Becker S. Tuchtenhagen F. Gouzoulis-Mayfrank E. (2001) Psychological profile of abstinent recreationl ecstasy (MDMA) users and significance of concomitant cannabis use. Hum Psychopharmacol 16: 627-633.
10. de Win MML. Schilt T. Reneman L. Vervaeke H. Jager G. Dijkin S. (2006) Ecstasy use and self-reported depression, impulsivity, and sensation seeking a prospective cohort study. J Psychopharmacol 20: 226-235.
11. Derogatis LR. Melisaratos N. (1983) The Brief Symptom Inventory: an introductory report. Psychol Med 13: 595-605.
12. Dughiero G. Schifano F. Forza G. (2001) Personality dimensions and psychopathological profiles of ecstasy users. Hum Psychopharmacol 16: 635-639.
13. Fox HC. Milani MR. Parrott AC. Turner JJD. (2001) Differences in premorbid adjustment between problematic and non-problematic ecstasy users. Canadian College of Neuropsychopharmacology (CCNP) Annual Meeting: 52 (abstract).
14. Gamma A. Buck A. Berthold Vollenweider FX. (2000) 3,4- Methylenedioxymethamphetamine (MDMA) modulates cortical and limbic brain activity as measured by [H215O]-PET in healthy humans. Neuropsychopharmacology 23: 389-395.
15. Gouzoulis-Mayfrank E. Daumann J. (2006) The confounding problem of polydrug use in recreational ecstasy/MDMA users: a brief overview. J Psychopharmacol 20: 189-193.
16. Hernández-López C. Farré M. Roset PN. (2002) 3,4-Methylenedioxymethamphethamine (ecstasy) and alcohol interactions in humans: Psychomotor performance, subjective effects, and pharmacokinetics. J Pharmacol and Experimental Therapeutics 300: 236-244.
17. Hopper JW. Si Z. Looby AR. Ryan ET. Penetar DM. Palmer CM. (2006) Incidence and patterns of polydrug use and craving for ecstasy in regular ecstasy users: An ecological momentary assessment study. Drug Alcohol Depend 85: 221-235.
18. Lamers CTJ. Bechara A. Rizzo M. Ramaekers JG. (2006) Cognitive function and mood in MDMA/THC users, THC users and non-drug using controls. J Psychopharmacol 20: 302-311.
19. Lavik NJ. Onstad S. (1986) Drug use and psychiatric symptoms in adolescence. Acta Psychiatr Scand 73: 437-440.
20. Lieb R. Schuetz CG. Pfister H. von Sydow K. Wittchen HU. (2002) Mental disorders in ecstasy users: a prospective-longitudinal investigation. Drug Alcohol Depend 68: 195-207.
21. Liechti ME. Baumann C. Gamma A. Vollenweider FX. (2000a) Acute psychological effects of 3,4-Methylenedioxymethamphethamine (MDMA, "Ecstasy") are attenuated by the serotonin uptake inhibitor citalopram. Neuropsychopharmacology 22: 513-521.
22. Liechti ME. Saur MR. Gamma A. Hell D. Vollenweider FX. (2000b) Psychological and Physiological effects of MDMA ("ecstasy") after pre-treatment with the 5-HT2 antagonist ketanserin in healthy humans. Neuropsychopharmacology 23: 396-404.
23. Liechti ME. Vollenweider FX. (2001) Which neuroreceptors mediate the subjective effects of MDMA in humans? A summary of mechanistic studies. Hum Psychopharmacol 16: 589-598.
24. MacInnes N. Handley SL. Harding GFA. (2001) Former chronic methylenedioxymethamphetaine (MDMA or ecstasy) users report mild depressive symptoms. J Psychopharmacol 15: 181-186.
25. Mass R. Bardong C. Kindl K. Dahome B. (2001) Relationship between cannabis use, schizotypal traits, and cognitive function in healthy subjects. Psychopathology 34: 209-214.
26. Medina KL. Shear PK. (2007) Anxiety, depression and behavioural symptoms of executive dysfunction in ecstasy users: contributions of polydrug use. Drug Alcohol Depend 87: 303-311.
27. Milani RM. Parrott AC. (2004) Psychological problems may be associated with ecstasy dependence rather than ecstasy lifetime dose. World J Biol Psychiatry 5: 130.
28. Milani RM. Parrott AC. Schifano F. Turner JJD. (2005) Patterns of cannabis use in ecstasy polydrug users: moderate cannabis use may compensate for self-rated aggression and somatic symptoms. Hum Psychopharmacol 20: 1-13.
29. Milani R. Turner JJD. Parrott AC. Parmar R. (2000) Recreational drug use and psychobiological problems, collaborative UK/Italy study (5). ecstasy (MDMA) polydrug user findings. J Psychopharmacol 14: PA22 (abstract).
30. Morgan MJ. McFie L. Fleetwood LH. Robinson JA. (2002) Ecstasy (MDMA). are the psychological problems associated with its use reversed by prolonged abstinence ? Psychopharmacology 159: 294-303.
31. Parrott AC. (2006) MDMA in humans: factors which affect the neuropsychobiological profiles of recreational ecstasy users, the integrative role of bioenergetic stress. J Psychopharmacol 20: 147-163.
32. Parrott AC. Buchanan T. Scholey AB. Heffernan T. Ling J. Rodgers J. (2002) Ecstasy/MDMA attributed problems reported by novice, moderate and heavy recreational users. Hum Psychopharmacol 17: 309-312.
33. Parrott AC. Milani RM. Gouzoulis-Mayfrank E. Daumann J. (2007) Cannabis and Ecstasy/MDMA (3,4-methylenedioxymethamphetamine). an analysis of their neuropsychobiological interactions in recreational users. J Neural Transm 114: 959-968.
34. Parrott AC. Milani RM. Parmar R. Turner JJD. (2001) Recreational ecstasy/MDMA and other drug users from the UK and Italy: psychiatric symptoms and psychobiological problems. Psychopharmacology 159: 77-82.
35. Parrott AC. Sisk E. Turner JJD. (2000) Psychobiological problems in heavy 'ecstasy' (MDMA) polydrug users. Drug Alcohol Depend 60: 105-110.
36. Pedersen W. Skrondal A. (1999) Ecstasy and new patterns of drug use: a normal population study. Addiction 94: 1695-1706.
37. Robbins JM. Kirmayer LJ. (1991) Attributions of common somatic symptoms. Psychol Med 21: 1029-1045.
38. Rodgers J. Buchanan T. Pearson C. Parrott AC. Long J. Heffernan T. (2006) Differential experiences of psychobiological sequelae of ecstasy use: quantitative and qualitative data from an internet study. J Psychopharmacol 20: 437-447.
39. Roiser JP. Sahakian BJ. (2004) Relationship between ecstasy use and depression: a study controlling fro polydrug use. Psychopharmacology 173: 411-417.
40. Scholey AB. Parrott AC. Buchanan T. Heffernan TM. Ling J. Rodgers J. (2004) Increased intensity of Ecstasy and polydrug usage in the more experience recreational Ecstasy/MDMA users: A WWW study. Addict Behav 29: 743-752.
41. Sherlock K. Connor M. (1999) Patterns of ecstasy use amongst club-goers on the UK 'dance scene'. Int J Drug Policy 10: 117-129.
42. Soar K;.Parrott AC;. (2002) Problematic ecstasy use: is it due to patterns of ecstasy use? J Psychopharmacol 16: G4, A58.
43. Soar K. Turner JJD. Parrott A. (2001) Psychiatric disorders in ecstasy (MDMA) users: a literature review focusing on personal predisposition and drug history. Hum Psychopharmacol Clin Exp 16: 641-645.
44. Soar K. Turner JJD. Parrott AC. (2006) Problematic versus non-problematic Ecstasy/MDMA use: the influence of drug usage patterns and pre-existing psychiatric factors. J Psychopharmacol 20: 417-724.
45. Strote J. Lee JE. Wechsler H. (2002) Increased MDMA use among college students: results of a national survey. J Adolesc Health 30: 64-72.
46. Thomasius R. Zapletalova P. Petersen K. Buchert R. Andersen B. Wartberg L. (2006) Mood, cognition and serotonin transporter availability in current and former ecstasy (MDMA) users: the longitudinal perspective. J Psychopharmacol 20: 211-225.
47. Topp L. Hando J. Dillon Roche A. Solowij N. (1999) Ecstasy use in Australia: patterns of use and associated harm. Drug Alcohol Depend 55: 105-115.
48. Verheyden SL. Henry JA. Curran VH. (2003a) Acute, sub-acute and long-term subjective consequences of 'ecstasy' (MDMA) consumption in 430 regular users. Hum Psychopharmacol 18: 507-517.
49. Verheyden SL. Maidment R. Curran VH. (2003b) Quitting ecstasy: An investigation of why people stop taking the drug and their subsequent mental health. J Psychopharmacol 17: 371-378.
50. Webb E. Ashton CH. Kelly P. Kamali F. (1996) Alcohol and drug use in the UK University students. Lancet 348: 922-925.
51. Winstock AR. Griffiths P. Stewart D. (2001) Drugs and the dance music scene: a survey of current drug is patterns among a sample o dance music enthusiasts in the UK. Drug Alcohol Depend 64: 9-17.